Fig. 1
Pyrotinib downregulates HER2 protein levels and suppresses phosphorylation of HER2, PI3K/AKT, and RAS/MAPK signaling pathways in SK-BR-3 and JIMT-1 cells. (a–d) Expression levels of HER2 and its downstream proteins in the PI3K/AKT and RAS/MAPK signaling pathways were analyzed by western blotting. (a) Both cell types were treated with lapatinib (0.001, 0.01, 0.1, 1 µM) for 24 h. (b) Both cell types were treated with lapatinib (1 µM) at different time points. (c) Both cell types were treated with pyrotinib (0.001, 0.01, 0.1, 1 µM) for 24 h. (d) Both cell types were treated with pyrotinib (0.1 µM) at different time points. Results are representative of 3 independent replicates.
